# CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT.

> **NCT02752243** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Peter Bader** · enrollment: 32 (actual)

## Conditions studied

- Myelodysplastic Syndromes
- Acute Leukemia

## Interventions

- **DRUG:** CIK-Cells

## Key facts

- **NCT ID:** NCT02752243
- **Lead sponsor:** Peter Bader
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-03
- **Primary completion:** 2023-03
- **Final completion:** 2024-03
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2022-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02752243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02752243, "CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02752243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*